[go: up one dir, main page]

MX2021008207A - Proteínas de fusión multifuncionales y usos de las mismas. - Google Patents

Proteínas de fusión multifuncionales y usos de las mismas.

Info

Publication number
MX2021008207A
MX2021008207A MX2021008207A MX2021008207A MX2021008207A MX 2021008207 A MX2021008207 A MX 2021008207A MX 2021008207 A MX2021008207 A MX 2021008207A MX 2021008207 A MX2021008207 A MX 2021008207A MX 2021008207 A MX2021008207 A MX 2021008207A
Authority
MX
Mexico
Prior art keywords
fusion proteins
functional fusion
fusion protein
functional
administering
Prior art date
Application number
MX2021008207A
Other languages
English (en)
Inventor
Mark L Tykocinski
Matthew C Weber
Carmella Romeo Smith
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2021008207A publication Critical patent/MX2021008207A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una proteína de fusión y a procedimientos de tratamiento que comprenden administrar una cantidad terapéuticamente eficaz de la proteína de fusión a un paciente que la necesite.
MX2021008207A 2019-01-07 2020-01-07 Proteínas de fusión multifuncionales y usos de las mismas. MX2021008207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789212P 2019-01-07 2019-01-07
PCT/US2020/012624 WO2020146423A1 (en) 2019-01-07 2020-01-07 Multi-functional fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2021008207A true MX2021008207A (es) 2021-11-04

Family

ID=71521906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008207A MX2021008207A (es) 2019-01-07 2020-01-07 Proteínas de fusión multifuncionales y usos de las mismas.

Country Status (12)

Country Link
US (1) US20220056102A1 (es)
EP (1) EP3908664A4 (es)
JP (1) JP7587505B2 (es)
KR (1) KR20220025698A (es)
CN (1) CN113518823B (es)
AU (1) AU2020207265A1 (es)
BR (1) BR112021013415A2 (es)
CA (1) CA3125748A1 (es)
IL (1) IL284679A (es)
MX (1) MX2021008207A (es)
SG (1) SG11202107454UA (es)
WO (1) WO2020146423A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3047707A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-41bbl fusion protein and methods of use thereof
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
WO2018127918A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirp alpha-cd70 fusion protein and methods of use thereof
CA3047708A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirpalpha-41bbl fusion protein and methods of use thereof
AU2019301315A1 (en) 2018-07-11 2021-02-11 Kahr Medical Ltd. PD1-4-1BBL variant fusion protein and methods of use thereof
WO2020012486A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
IL299672A (en) * 2020-07-03 2023-03-01 Univ Columbia Multipurpose vertical protein chimeras
WO2022188129A1 (zh) * 2021-03-12 2022-09-15 利时雨 广谱趋化因子受体抑制剂增强新冠肺炎病毒感染的细胞免疫的分子机制及在其药物防治中的应用
WO2023200311A1 (ko) * 2022-04-15 2023-10-19 주식회사 아이엠바이오로직스 반감기가 향상된 융합단백질 플랫폼

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171152A4 (en) * 2000-02-03 2002-09-25 Univ Jefferson VMIP-II PEPTIDE ANTAGONISTS OF CXCR4
US7897152B2 (en) * 2000-09-18 2011-03-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-antigen fusion proteins
CN1511040A (zh) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
EP2950814A4 (en) * 2013-01-31 2016-06-08 Univ Jefferson FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害
MX2017015811A (es) * 2015-06-12 2018-04-10 Squibb Bristol Myers Co Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
EP3378871A4 (en) * 2015-11-17 2019-08-07 Suzhou Suncadia Biopharmaceuticals Co., Ltd. PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF
GB201521383D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
MY186414A (en) * 2015-12-15 2021-07-22 Gilead Sciences Inc Human immunodeficiency virus neutralizing antibodies
EP3433269B1 (en) * 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
KR102687833B1 (ko) * 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
US20200093789A1 (en) * 2017-05-10 2020-03-26 The General Hospital Corporation Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor
AU2018267843B2 (en) * 2017-05-16 2025-01-23 Jiangsu Hengrui Medicine Co., Ltd. PD-L1 antibody pharmaceutical composition and use thereof
WO2018218215A1 (en) * 2017-05-26 2018-11-29 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
GB201709808D0 (en) * 2017-06-20 2017-08-02 Kymab Ltd Antibodies
AU2018290228B2 (en) * 2017-06-21 2021-07-01 Gilead Sciences, Inc. Multispecific antibodies that target HIV gp120 and CD3

Also Published As

Publication number Publication date
CN113518823B (zh) 2025-05-02
KR20220025698A (ko) 2022-03-03
EP3908664A4 (en) 2023-01-25
JP7587505B2 (ja) 2024-11-20
CA3125748A1 (en) 2020-07-16
US20220056102A1 (en) 2022-02-24
SG11202107454UA (en) 2021-08-30
IL284679A (en) 2021-08-31
CN113518823A (zh) 2021-10-19
BR112021013415A2 (pt) 2021-12-28
WO2020146423A1 (en) 2020-07-16
EP3908664A1 (en) 2021-11-17
JP2022528030A (ja) 2022-06-08
AU2020207265A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
PH12020500648A1 (en) Il-15 variants and uses thereof
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
WO2019032662A8 (en) Clec9a binding agents and use thereof
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
PH12015502063A1 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
PH12018500098A1 (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2022004577A (es) Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
SA523440622B1 (ar) أجسام مضادة
MX2018014716A (es) Anticuerpos anti-tnfrsf25.
PH12021551494A1 (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
EP4406613A3 (en) Immunogenic arginase peptides
MX2019006444A (es) Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
EA202192460A1 (ru) Синтетические нейромодуляторные пептиды